Quidelortho Sales Company, LLC

Quidelortho Sales Company, LLC, a HUBZone-certified joint venture based in San Diego, California, supplies medical diagnostic equipment, laboratory analyzers, reagents, and clinical testing consumables to federal healthcare agencies as a prime contractor (99% of recent awards) and occasional subcontractor. The vendor is a child entity of Ortho-Clinical Diagnostics, Inc., a manufacturer of diagnostic instruments and reagents, and operates primarily through the GSA Critical Analyzers, Laboratory (FSS-66-III) schedule, where it holds 234 task orders valued at $86.9 million combined.

Quidelortho's customer concentration is heavily weighted toward civilian and defense healthcare. The top five funding agencies by award count account for 74% of all awards, led by the Indian Health Service (75 awards, $21.1 million) and the Defense Health Agency (66 awards, $44.4 million combined potential value), followed by Defense Logistics Agency Troop Support Medical (50 awards), Veterans Integrated Service Network 10 (12 awards, $1.1 million), and Veterans Integrated Service Network 23 (8 awards, $9.8 million). The potential-value ranking differs: DHA dominates dollars at $44.4 million, followed by the Defense Logistics Agency (3 awards but $22.5 million ceiling), IHS ($21.1 million), and VISN 23 ($9.8 million). Quidelortho competes predominantly full-and-open across all these customer agencies; HUBZone set-asides are rarely applied to its awards despite certification status.

Recent capability work exemplifies the vendor's portfolio. Representative awards include a $1.2 million Defense Health Agency delivery order for chemistry immunoassay analyzer lease, supplies, and reagents at Fort Campbell, Kentucky (awarded October 1, 2025, through September 30, 2030) under the GSA schedule; an $844.8 thousand Indian Health Service delivery order for clinical chemistry analyzer cost-per-test services for the Western Oregon Service Unit (awarded May 1, 2026, through April 30, 2031) under the GSA schedule; a $734.8 thousand Defense Health Agency delivery order for a VITROS XT7600 Chemistry Analyzer with full clinical chemistry and immunoassay menu in Denver, Colorado (awarded October 1, 2024, through September 30, 2029); a $696.9 thousand Veterans Integrated Service Network 23 BPA call for ortho immunochemistry supplies (awarded October 1, 2025, through September 30, 2026); and a $602.1 thousand delivery order from the NIH Office of Logistics and Acquisition Operations for instrument lease and reagents supplies in Raritan, New Jersey (awarded April 1, 2025, through September 30, 2026). The work spans blood bank gel reagents, chemistry analyzers, cost-per-reportable-result testing services, immunochemistry systems, and specialized laboratory consumables across military treatment facilities, Veterans Affairs medical centers, Indian Health Service facilities, federal correctional complexes, and NIH Clinical Center locations.

The vendor holds a multi-year $22.5 million Indefinite Delivery Contract (SPE2DF) with the Defense Logistics Agency awarded December 10, 2025, through December 9, 2030, under the ELECTR CAT (ECAT) II DIV program for laboratory equipment, supplies, and related items to federal laboratories. Additionally, Quidelortho maintains multiple single-award indefinite delivery contracts and blanket purchase agreements across federal agencies: a $2.48 million Defense Health Agency contract for dry chemistry analyzers at Military Entrance Processing Stations (September 3, 2025 through August 31, 2028); a $1.85 million Defense Health Agency indefinite delivery contract for immunochemistry and clinical chemistry analyzer leases at Great Lakes West Army Community Hospital (October 1, 2025 through September 30, 2030); a $2.28 million Defense Health Agency contract for immunoassay testing and equipment at Reynolds Army Health Clinic, Fort Sill (April 1, 2024 through March 30, 2029); a $6.86 million Veterans Integrated Service Network 23 blanket purchase agreement for ortho immunochemistry supplies (October 1, 2023 through September 30, 2026); a $1.17 million Veterans Integrated Service Network 1 blanket purchase agreement for blood bank gel testing supplies (November 15, 2022 through November 14, 2027); a $1.65 million Veterans Integrated Service Network 23 blanket purchase agreement for chemistry and immunochemistry base and option services (June 1, 2023 through May 31, 2028); and a $375 thousand Veterans Integrated Service Network 17 blanket purchase agreement for blood bank testing equipment and reagents (June 1, 2025 through May 31, 2027). The vendor also holds a $350 thousand Indian Health Service blanket purchase agreement for Triage Meter Pro diagnostic equipment (September 22, 2025 through September 30, 2030).

Activity trajectory shows sustained growth: 23 awards in 2022, 28 in 2023, 42 in 2024, 92 in 2025, and 72 in 2026 year-to-date. Seventy-nine awards with ultimate completion dates in the next twenty-four months carry combined potential value of $30.9 million, representing significant recompete exposure and opportunity for competitors. In its rare subcontractor role, Quidelortho supplies medical diagnostic test kits and supplies to Cardinal Health 200, LLC on routine delivery orders for immunochemistry testing kits and surgical dressing supplies.

The vendor's core capability portfolio centers on blood bank and immunohematology analyzers (gel-based and automated cost-per-test systems), clinical chemistry analyzers on lease and cost-per-reportable-result bases, immunochemistry systems, laboratory reagents and consumables (blood bank gel products, chemistry controls, diagnostic test kits including QuickVue+ and Sofia rapid diagnostics), and preventive maintenance and service support for diagnostic equipment. Primary NAICS coding reflects this: 198 awards carry Analytical Laboratory Instrument Manufacturing (334516), 53 carry Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (425620), and 27 carry In-Vitro Diagnostic Substance Manufacturing (325413). PSC distribution emphasizes Laboratory Equipment and Supplies (91 awards), In Vitro Diagnostic Substances (54 awards), and Medical and Surgical Instruments and Equipment (50 awards).

Quidelortho's federal footprint spans 35 distinct customer agencies, including military treatment facilities at Fort Campbell, Fort Meade, Fort Stewart, McConnell Air Force Base, Minot Air Force Base, Seymour Johnson Air Force Base, Columbus Air Force Base, Malmstrom Air Force Base, Beale Air Force Base, Edwards Air Force Base, Great Lakes West Army Community Hospital, and Naval Hospital Pensacola; Veterans Affairs medical centers across multiple VISNs (1, 4, 5, 6, 7, 8, 9, 10, 15, 16, 17, 19, 20, 22, 23); Indian Health Service facilities in the Great Plains and Southwest (Pine Ridge, Sisseton, Rosebud, Fort Yates, Belcourt, Kayenta, Tonalea, Lawton, Whiteriver, Hopi, and others); the Centers for Disease Control and Prevention; the National Institutes of Health Clinical Center and Department of Transfusion Medicine; the Department of the Navy; the Military Sealift Command (USNS Comfort); Federal Correctional Complex Butner, Federal Medical Center Devens, and Federal Bureau of Prisons facilities; and the Air Force Office of Scientific Research. The vendor competes full-and-open across all agencies and does not rely on set-aside programs despite HUBZone certification.